Trever G Bivona

Trever G Bivona

UNVERIFIED PROFILE

Are you Trever G Bivona?   Register this Author

Register author
Trever G Bivona

Trever G Bivona

Publications by authors named "Trever G Bivona"

Are you Trever G Bivona?   Register this Author

88Publications

2672Reads

38Profile Views

AXL targeting abrogates autophagic flux and induces immunogenic cell death in drug resistant cancer cells.

J Thorac Oncol 2020 Feb 1. Epub 2020 Feb 1.

Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, Norway; Department of Biomedicine, University of Bergen, Bergen, Norway; Inserm Unit 1186 Comprehensive Cancer Center, Institut Gustave Roussy, Villejuif, France. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2020.01.015DOI Listing
February 2020

Overcoming the challenges of cancer drug resistance through bacterial-mediated therapy.

Chronic Dis Transl Med 2019 Dec 8;5(4):258-266. Epub 2020 Jan 8.

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cdtm.2019.11.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004931PMC
December 2019

Betacellulin drives therapy-resistance in glioblastoma.

Neuro Oncol 2019 Nov 3. Epub 2019 Nov 3.

Department of Neurology, University of California, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noz206DOI Listing
November 2019

Targeting Oncogenic BRAF: Past, Present, and Future.

Cancers (Basel) 2019 Aug 16;11(8). Epub 2019 Aug 16.

Department of Medicine, University of California, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11081197DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721448PMC
August 2019

Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers.

Cell Rep 2019 Aug;28(9):2317-2330.e8

Department of Medicine, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158, USA; QB3, California Institute for Quantitative Biosciences, San Francisco, CA 94158, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2019.07.063DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728083PMC
August 2019

Immunohistochemistry to Study YAP in Human Tissue Samples.

Methods Mol Biol 2019 ;1893:89-95

Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-8910-2_7DOI Listing
June 2019

Engineering Multidimensional Evolutionary Forces to Combat Cancer.

Cancer Discov 2019 05 16;9(5):587-604. Epub 2019 Apr 16.

Department of Medicine, University of California, San Francisco, California.

View Article

Download full-text PDF

Source
http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-18-1196DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497542PMC
May 2019

Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.

Clin Lung Cancer 2019 03 20;20(2):e137-e141. Epub 2018 Nov 20.

Department of Medicine, University of California, San Francisco, San Francisco, CA; Hellen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.11.003DOI Listing
March 2019

Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology.

Trends Mol Med 2019 03 24;25(3):185-197. Epub 2019 Jan 24.

Department of Medicine, University of California, San Francisco, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14714914193000
Publisher Site
http://dx.doi.org/10.1016/j.molmed.2018.12.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401263PMC
March 2019

Polytherapy and Targeted Cancer Drug Resistance.

Trends Cancer 2019 Mar 26;5(3):170-182. Epub 2019 Feb 26.

Department of Medicine, University of California, San Francisco, 600 16(th) Street, Box 2140, Genentech Hall, San Francisco, CA 94158, USA; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, 600 16(th) Street, Box 2140, Genentech Hall, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 600 16(th) Street, Box 2140, Genentech Hall, San Francisco, CA 94158, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trecan.2019.02.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446041PMC
March 2019

Dampening oncogenic RAS signaling.

Authors:
Trever G Bivona

Science 2019 03;363(6433):1280-1281

Department of Medicine, Cellular and Molecular Pharmacology, and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94158, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/science.aav6703DOI Listing
March 2019

Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.

Curr Oncol Rep 2019 02 26;21(3):21. Epub 2019 Feb 26.

Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0770-xDOI Listing
February 2019

Circulating tumor DNA analysis in patients with EGFR mutant lung cancer.

J Thorac Dis 2018 Nov;10(Suppl 33):S4061-S4064

Department of Medicine, University of California, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.09.106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297447PMC
November 2018

Emerging application of genomics-guided therapeutics in personalized lung cancer treatment.

Ann Transl Med 2018 May;6(9):160

Department of Medicine, University of California, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2018.05.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985272PMC
May 2018

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.

EBioMedicine 2018 03 5;29:112-127. Epub 2018 Feb 5.

Pangaea Oncology, Laboratory of Molecular Biology, Coyote Reserach Group, Quirón-Dexeus University Institute, Barcelona, Spain; Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, Spain; Instituto Oncológico Dr Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain; Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ebiom.2018.02.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5925453PMC
March 2018

The evolving understanding of immunoediting and the clinical impact of immune escape.

J Thorac Dis 2018 Mar;10(3):1248-1252

Department of Medicine, University of California, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.03.60DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906217PMC
March 2018

Imaging PD-L1 Expression with ImmunoPET.

Bioconjug Chem 2018 01 15;29(1):96-103. Epub 2017 Nov 15.

Department of Radiology and Biomedical Imaging, ‡Department of Medicine, §Helen Diller Family Comprehensive Cancer Center, ∥Department of Pharmaceutical Chemistry, and ⊥Department of Radiation Oncology, University of California, San Francisco , 505 Parnassus Avenue, San Francisco, California 94143, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.bioconjchem.7b00631DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773933PMC
January 2018

Current Landscape of Targeted Therapy in Lung Cancer.

Clin Pharmacol Ther 2017 Nov 25;102(5):757-764. Epub 2017 Sep 25.

Department of Medicine, University of California, San Francisco, San Francisco, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cpt.810DOI Listing
November 2017

Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer.

Cancers (Basel) 2017 Nov 30;9(12). Epub 2017 Nov 30.

Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers9120164DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5742812PMC
November 2017

Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer.

Nat Commun 2017 10 10;8(1):823. Epub 2017 Oct 10.

State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200240, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-017-00963-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634994PMC
October 2017

Understanding and targeting resistance mechanisms in NSCLC.

Nat Rev Cancer 2017 10;17(11):637-658

Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, 505 Parnassus Avenue, Box 1270, San Francisco, California 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc.2017.84DOI Listing
October 2017

Metastasis: From head to tail.

Cell Cycle 2017 03 5;16(6):487-488. Epub 2017 Jan 5.

a Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco , San Francisco , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384101.2016.1271636DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384580PMC
March 2017

Dividing and conquering the variation among variants in lung cancer.

Authors:
Trever G Bivona

Transl Cancer Res 2017 Mar;6(Suppl 2):S369-S370

Department of Medicine, University of California at San Francisco, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tcr.2017.03.25DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319928PMC
March 2017

Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma.

NPJ Precis Oncol 2017 20;1. Epub 2017 Mar 20.

Department of Medicine, University of California at San Francisco, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41698-017-0007-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687582PMC
March 2017

HSP70 dependence in rhabdomyosarcoma: Seed or soil?

Cell Cycle 2017 01 29;16(2):147-148. Epub 2016 Sep 29.

b Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco , San Francisco , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384101.2016.1237168DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5283818PMC
January 2017

RAS signaling in ALK fusion lung cancer.

Small GTPases 2016 22;7(1):32-3. Epub 2016 Feb 22.

a Department of Medicine , University of California at San Francisco , San Francisco , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/21541248.2015.1131803DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905280PMC
December 2016

RAS-MAPK in ALK targeted therapy resistance.

Cell Cycle 2015 ;14(23):3661-2

a Department of Medicine ; University of California at San Francisco ; San Francisco , CA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384101.2015.1096103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4825705PMC
October 2016

An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer.

Cancer Lett 2016 09 22;380(1):144-52. Epub 2016 Jun 22.

Department of Urology, University of California, San Francisco (UCSF), San Francisco, CA, USA; Division of Hematology & Oncology, University of California, San Francisco (UCSF), San Francisco, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2016.06.017DOI Listing
September 2016

Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance.

Clin Lung Cancer 2016 09 8;17(5):466-469. Epub 2016 Jun 8.

Division of Medical Oncology, Department of Medicine, University of Colorado, Denver, Aurora, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.05.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378381PMC
September 2016

Combined chemical-genetic approach identifies cytosolic HSP70 dependence in rhabdomyosarcoma.

Proc Natl Acad Sci U S A 2016 08 22;113(32):9015-20. Epub 2016 Jul 22.

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94143; Department of Medicine, University of California, San Francisco, CA 94143;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1603883113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987817PMC
August 2016

A framework for understanding and targeting residual disease in oncogene-driven solid cancers.

Nat Med 2016 05;22(5):472-8

Department of Medicine and Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.4091DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384713PMC
May 2016

RAS-MAPK signaling influences the efficacy of ALK-targeting agents in lung cancer.

Mol Cell Oncol 2016 Mar 29;3(2):e1091061. Epub 2015 Oct 29.

Division of Hematology and Medical Oncology, University of California San Francisco, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/23723556.2015.1091061DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905399PMC
March 2016

AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.

PLoS One 2015 17;10(3):e0119832. Epub 2015 Mar 17.

Department of Pulmonology and Critical Care Medicine, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea; Department of Oncology, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0119832PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363657PMC
February 2016

Tracking Down Response and Resistance to TRK Inhibitors.

Cancer Discov 2016 Jan;6(1):14-6

Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco, San Francisco, California. Helen Diller Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-15-1352DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709026PMC
January 2016

The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors.

Mol Cell Oncol 2016 Jan 27;3(1):e1021441. Epub 2015 Apr 27.

Division of Hematology and Medical Oncology; University of California San Francisco; San Francisco, CA USA; Helen Diller Family Comprehensive Cancer Center; University of California San Francisco; San Francisco, CA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/23723556.2015.1021441DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845171PMC
January 2016

Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas.

Cancer Discov 2015 Oct 24;5(10):1040-8. Epub 2015 Jun 24.

Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California. Department of Medicine, University of California, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-15-0274DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4592417PMC
October 2015

YAP in MAPK pathway targeted therapy resistance.

Cell Cycle 2015 ;14(12):1765-6

a Department of Medicine ; Boston , MA USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384101.2015.1032644DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612653PMC
August 2015

NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.

Cell Rep 2015 Apr 2;11(1):98-110. Epub 2015 Apr 2.

Department of Medicine, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2015.03.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394036PMC
April 2015

AXL receptor tyrosine kinase as a therapeutic target in NSCLC.

Lung Cancer (Auckl) 2015 30;6:27-34. Epub 2015 Apr 30.

Division of Hematology and Medical Oncology, University of California San Francisco, San Francisco, CA, USA; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/LCTT.S60438DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217513PMC
April 2015

Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer.

Proc Natl Acad Sci U S A 2014 Feb 3;111(7):E748-57. Epub 2014 Feb 3.

Departments of Medicine and Epidemiology and Biostatistics and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94158.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1320956111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932924PMC
February 2014

Recent advances in personalized lung cancer medicine.

Per Med 2014 ;11(3):309-321

Division of Hematology & Medical Oncology, University of California San Francisco, San Francisco, CA, USA ; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263209PMC
http://dx.doi.org/10.2217/pme.14.19DOI Listing
January 2014

Genetics and biomarkers in personalisation of lung cancer treatment.

Lancet 2013 Aug;382(9893):720-31

Catalan Institute of Oncology Badalona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(13)61715-8DOI Listing
August 2013

FGFR fusions in the driver's seat.

Cancer Discov 2013 Jun;3(6):607-9

Department of Pediatrics, University of California San Francisco, San Francisco, CA 94158, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0185DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4988530PMC
June 2013

Mechanisms of resistance to EGFR targeted therapies.

Cancer Biol Ther 2013 Apr 28;14(4):304-14. Epub 2013 Jan 28.

Department of Medicine, Division of Hematology and Oncology, Helen Diller Comprehensive Cancer Center University of California San Francisco, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.23627DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667869PMC
April 2013

Secrets of drug resistance in NSCLC exposed by new molecular definition of EMT.

Clin Cancer Res 2013 Jan 21;19(1):3-5. Epub 2012 Nov 21.

Department of Medicine, Division of Hematology and Oncology, Helen Diller Comprehensive Cancer Center, University of California, San Francisco, CA 94158, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-3232DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3537879PMC
January 2013

Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.

Cancer Discov 2012 Oct;2(10):872-5

Department of Medicine, Division of Hematology and Oncology, University of California at San Francisco San Francisco, California 94158, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-12-0387DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3475614PMC
October 2012

Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients.

Chemother Res Pract 2012 29;2012:817297. Epub 2012 Aug 29.

Division of Hematology/Oncology, Department of Medicine, USCF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.

View Article

Download full-text PDF

Source
https://www.hindawi.com/archive/2012/817297/
Publisher Site
http://dx.doi.org/10.1155/2012/817297DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437267PMC
September 2012

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.

Nature 2011 Mar;471(7339):523-6

Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 20, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nature09870
Publisher Site
http://dx.doi.org/10.1038/nature09870DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541675PMC
March 2011

Analysis of Ras activation in living cells with GFP-RBD.

Methods Enzymol 2006 ;407:128-43

Department of Pathology, New York University Cancer Institute, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0076-6879(05)07012-6DOI Listing
June 2008

Analysis of K-Ras phosphorylation, translocation, and induction of apoptosis.

Methods Enzymol 2008 ;439:87-102

Department of Medicine, Cancer Institute, New York University School of Medicine, New York, NY, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S007668790700407
Publisher Site
http://dx.doi.org/10.1016/S0076-6879(07)00407-7DOI Listing
June 2008

Analysis of Ras and Rap activation in living cells using fluorescent Ras binding domains.

Methods 2005 Oct;37(2):138-45

Department of Medicine, NYU School of Medicine, 550 First Avenue, New York, NY 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ymeth.2005.05.022DOI Listing
October 2005

Cannabinoid receptor-induced neurite outgrowth is mediated by Rap1 activation through G(alpha)o/i-triggered proteasomal degradation of Rap1GAPII.

J Biol Chem 2005 Mar 18;280(12):11413-21. Epub 2005 Jan 18.

Department of Pharmacology and Biological Chemistry, Mount Sinai School of Medicine, New York, New York 10029, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M411521200DOI Listing
March 2005

Membranes as messengers in T cell adhesion signaling.

Nat Immunol 2004 Apr;5(4):363-72

Program in Molecular Pathogenesis, Skirball Institute of Biomolecular Medicine and the Department of Pathology, NYU School of Medicine, New York, New York 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ni1057DOI Listing
April 2004

Identification of a Ras GTPase-activating protein regulated by receptor-mediated Ca2+ oscillations.

EMBO J 2004 Apr 1;23(8):1749-60. Epub 2004 Apr 1.

Inositide Group, Henry Wellcome Integrated Signalling Laboratories, Department of Biochemistry, School of Medical Sciences, University of Bristol, Bristol, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.emboj.7600197DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC394250PMC
April 2004

Rap1 up-regulation and activation on plasma membrane regulates T cell adhesion.

J Cell Biol 2004 Feb;164(3):461-70

Deparment of Cell Biology, New York University School of Medicine, 550 First Ave., New York, NY 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1083/jcb.200311093DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2172240PMC
February 2004

Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment.

Mol Cell 2004 Feb;13(3):341-55

Cancer Biology Program, Division of Hematology-Oncology, Department of Medicine, Beth Israel-Deaconess Medical Center and Harvard Medical School, Boston, MA 02115 USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1097-2765(04)00050-4DOI Listing
February 2004

Intersectin activates Ras but stimulates transcription through an independent pathway involving JNK.

J Biol Chem 2003 Nov 11;278(47):47038-45. Epub 2003 Sep 11.

Laboratory of Signal Transduction, National Institute of Environmental Health Services, NIH/DHHS, Building 101, Research Triangle Park, NC 27709, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M303895200DOI Listing
November 2003

Phospholipase Cgamma activates Ras on the Golgi apparatus by means of RasGRP1.

Nature 2003 Aug 29;424(6949):694-8. Epub 2003 Jun 29.

Department of Medicine, New York University School of Medicine, 550 First Avenue, New York, New York 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature01806DOI Listing
August 2003

Ras pathway signaling on endomembranes.

Curr Opin Cell Biol 2003 Apr;15(2):136-42

Departments of Medicine, Cell Biology and Pharmacology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0955-0674(03)00016-4DOI Listing
April 2003